Brooks S. Edwards
Mayo Clinic
Internal medicineUrologyCalcineurinEndocrinologySurgeryPathologyRenal functionCardiologyHazard ratioSirolimusAtrial natriuretic peptideHeart failureVentricular assist deviceHeart transplantationImmunosuppressionCardiac allograft vasculopathyTransplantationContinuous flowMedicine
257Publications
50H-index
7,416Citations
Publications 256
Newest
#1Hilmi Alnsasra (BGU: Ben-Gurion University of the Negev)H-Index: 4
#2Rabea Asleh (HUJI: Hebrew University of Jerusalem)H-Index: 19
Last. Sudhir S. Kushwaha (Mayo Clinic)H-Index: 53
view all 9 authors...
Background and Purpose: Less is known about the risk factors and outcomes associated with stroke in the current era of increasing heart transplantation (HT) being performed in older patients. The i...
Source
#7Wei Guo (UW: University of Wyoming)
Source
Purpose Stroke after heart transplantation (HT) is a major cause of morbidity and mortality. Less is known about the risk factors associated with stroke in the current era of increasing HT being performed in older patients and with advances in immunosuppressive (IS) therapies. We aimed to determine the incidence, predictors and outcomes of stroke after HT. Methods We examined the incidence of ischemic and hemorrhagic strokes and associated outcomes in all consecutive adults who underwent HT betw...
Source
#1Rabea Asleh (HUJI: Hebrew University of Jerusalem)H-Index: 19
#2Alexandros Briasoulis (UIHC: University of Iowa Hospitals and Clinics)H-Index: 26
Last. Sudhir S. Kushwaha (Mayo Clinic)H-Index: 53
view all 14 authors...
BACKGROUND Enhanced platelet reactivity may play a role in cardiac allograft vasculopathy (CAV) progression. The use of antiplatelet agents after heart transplantation (HT) has been inconsistent and although aspirin (ASA) is often a part of the medication regimen after HT, limited evidence is available on its benefit. METHODS AND RESULTS CAV progression was assessed by measuring the difference in plaque volume and plaque index between the last follow-up and the baseline coronary intravascular ul...
Source
#1Richard C. Daly (Mayo Clinic)H-Index: 77
#2Andrew N. Rosenbaum (Mayo Clinic)H-Index: 10
Last. Sudhir S. Kushwaha (Mayo Clinic)H-Index: 53
view all 17 authors...
Abstract Background In patients undergoing heart transplantation, significant allosensitization limits access to organs, resulting in longer wait times and high waitlist mortality. Current desensitization strategies are limited in enabling successful transplantation. Objectives The purpose of this study was to describe the cumulative experience of combined heart-liver transplantation using a novel heart-after-liver transplant (HALT) protocol resulting in profound immunologic protection. Methods ...
2 CitationsSource
#1Rabea Asleh (Mayo Clinic)H-Index: 19
#2Hilmi Alnsasra (Mayo Clinic)H-Index: 4
Last. Sudhir S. Kushwaha (Mayo Clinic)H-Index: 53
view all 11 authors...
We have previously described the use of sirolimus (SRL) as primary immunosuppression following heart transplantation (HT). The advantages of this approach include attenuation of cardiac allograft vasculopathy (CAV), improvement in glomerular filtration rate (GFR) and reduced malignancy. However, in some patients SRL may cause significant proteinuria. We sought to investigate the prognostic value of proteinuria after conversion to SRL. CAV progression and adverse clinical events were studied. CAV...
3 CitationsSource
#7Wei Guo (UW: University of Wyoming)
Ribonucleoprotein (RNP) granules are biomolecular condensates-liquid-liquid phase-separated droplets that organize and manage messenger RNA metabolism, cell signaling, biopolymer assembly, biochemical reactions and stress granule responses to cellular adversity. Dysregulated RNP granules drive neuromuscular degenerative disease but have not previously been linked to heart failure. By exploring the molecular basis of congenital dilated cardiomyopathy (DCM) in genome-edited pigs homozygous for an ...
11 CitationsSource
#1J.A. Steadman (Mayo Clinic)
#2John M. Stulak (Mayo Clinic)H-Index: 44
Last. Richard C. Daly (Mayo Clinic)H-Index: 77
view all 12 authors...
Purpose Candidate selection for multi-organ transplants should consider the chances of good function and benefit of all transplanted organs. Risk factors for early renal graft dysfunction after combined heart-kidney transplant (CHKTx) may include vasoplegia and vasopressor need in spite of good cardiac graft function. We aimed to identify risk factors for vasoplegia after CHKTx and its impact on postoperative and renal allograft outcomes. Methods A retrospective review was conducted on 58 consec...
Source
#1Rabea Asleh (Mayo Clinic)H-Index: 19
#2Hilmi Alnsasra (Mayo Clinic)H-Index: 4
Last. Sudhir S. Kushwaha (Mayo Clinic)H-Index: 53
view all 10 authors...
We have previously described the use of sirolimus (SRL) as primary immunosuppression therapy following heart transplantation (HT). The advantages of this approach include attenuation of cardiac allograft vasculopathy (CAV), improvement in glomerular filtration rate (GFR) and a decrease in rates of
Source
#1Rabea Asleh (Mayo Clinic)H-Index: 19
#2Alexandros Briasoulis (Mayo Clinic)H-Index: 26
Last. Sudhir S. Kushwaha (Mayo Clinic)H-Index: 53
view all 12 authors...
Enhanced platelet reactivity may play a role in the development and progression of cardiac allograft vasculopathy (CAV). The use of anti-platelet agents following heart transplantation (HT) has been inconsistent and although aspirin is often a part of the medication regimen after HT, limited
3 CitationsSource